Brevan Howard Capital Management’s Quest Diagnostics DGX Stock Holding History

Brevan Howard Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$354K	Sell	1,806 -10,118	-85%	-$1.97M	﹤0.01%	1518
2025 Q4	$2.07M	Buy	11,924 +10,293	+631%	+$1.87M	0.02%	480
2025 Q3	$311K	Buy	1,631 +471	+41%	+$83.6K	﹤0.01%	1549
2025 Q2	$208K	Buy	+1,160	New	+$201K	﹤0.01%	1697
2024 Q4	–	Sell	-4,647	Closed	-$721K	–	1128
2024 Q3	$721K	Sell	4,647 -1,124	-19%	-$168K	0.01%	569
2024 Q2	$790K	Buy	5,771 +2,056	+55%	+$282K	0.01%	449
2024 Q1	$495K	Buy	+3,715	New	+$482K	﹤0.01%	470

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Brevan Howard Capital Management's DGX Position: Q1 2026 in Review

Brevan Howard Capital Management reduced its Quest Diagnostics (DGX) stake by 85% in Q1 2026, selling an estimated $1.97M and leaving 1,806 shares worth $354K. The position accounts for ﹤0.01% of the portfolio, ranked #1518.

Brevan Howard Capital Management first reported a position in DGX in Q1 2024 and has held it in 7 quarters since. The position peaked at $2.07M in Q4 2025. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Brevan Howard Capital Management held 1,806 shares of Quest Diagnostics worth $354K as of Q1 2026.
Brevan Howard Capital Management sold 10,118 Quest Diagnostics shares in Q1 2026, an estimated $1.97M.
Quest Diagnostics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1518 holding.
Brevan Howard Capital Management first reported a position in Quest Diagnostics in Q1 2024 and has held it in 7 quarters since.
Brevan Howard Capital Management's Quest Diagnostics position peaked at $2.07M in Q4 2025.
1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.